Pluriomics receives a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery

Leiden, June 16, 2016 – Pluriomics, an emerging Dutch/Belgian biotechnology company whose mission is to deliver innovative human cardiomyocyte assays for use in drug discovery & development, today announced it was awarded a prestigious EU SME instrument grant. This grant gives Pluriomics the opportunity to advance cardiovascular drug discovery, in order to reduce the development […]

READ MORE read more

Pluriomics in €2M alliance to develop in vitro heart failure models

Leiden, The Netherlands, May 2016: Pluriomics, a Dutch biotech company focusing on the development of fully functional human stem cell-based assay systems, today announced that it will lead a €2.0 million Eurostars consortium for the development of a novel in vitro organ-on-a-chip heart failure model for drug discovery and development. In this 3 years project, […]

READ MORE read more

News archive

MipTec – BLSW 2016

Date: September 20-22, 2016 Location: Basel, Switzerland Pluriomics will be present at MipTec 2016 during the Basel Life Science Week (BLSW) at September 20th. On Tuesday, September 20th (16:15 – 16:45), Dr. Marijn Vlaming, VP Technology at Pluriomics, will give a talk entitled “Assessment of anti-cancer drug induced cardiotoxicity in human induced pluripotent stem cell (hiPSC) derived […]

READ MORE read more

SPS annual meeting 2016 – Vancouver

Pluriomics will be presenting and exhibiting at the Safety Pharmacology Society (SPS) 16th annual meeting, September 18 – 21 in Vancouver, BC, Canada. Where can you find us? Come to visit us at booth #506 to hear all about our recent developments, new products and applications.  Don’t miss our posters and the chance to chat with us at the poster […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in drug discovery and development. The kit includes both Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Our solutions